12.10SEK-4.57%Mkt Cap: 53.86M $P/E: —1d ago
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassi…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap53.86M $
Enterprise Value13.41M $
Revenue (TTM)6.46M $
Gross Profit6.46M $
Net Income (TTM)-17.60M $
Revenue/Share0.1388 USD
Last Price12.10 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees17
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0020388577
Valuation
P/E (Trailing)—
P/E (Forward)-2.14
PEG—
EV/EBITDA-0.58
EV/Revenue2.08
P/S8.34
P/B2.00
EPS (TTM)-5.14
EPS (Forward)—
52W Range
10.6017% of range19.64
52W High19.64 SEK
52W Low10.60 SEK
Profitability
Gross Margin100.00%
Oper. Margin-905.28%
EBITDA Margin0.00%
Profit Margin-320.12%
ROE-49.80%
ROA-33.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.14M $
CapEx (TTM)108.47K $
FCF Margin-91.32%
FCF Yield-10.95%
Net Debt-40.45M $
Net Debt/EBITDA1.76
Balance Sheet
Debt/Equity0.02
Current Ratio2.89
Quick Ratio2.77
Book Value/Sh6.039 SEK
Cash/Share10.22 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)46.25 SEK
Upside (mean)+282.2%
Target Range25.00 SEK – 70.00 SEK
SEK25.00+282.2% to meanSEK70.00
# Analysts4
Ownership
Shares Out.46.54M
Float34.29M
Insiders37.57%
Institutions32.84%
Technical
SMA 5011.81 (+2.4%)
SMA 20015.71 (-23.0%)
Beta-0.07
S&P 52W Chg19.63%
Avg Vol (30d)53.45K
Avg Vol (10d)68.86K
Technical Indicators
RSI (14)54.4
MACD0.0397
MACD Signal-0.1149
MACD Hist.+0.1546
BB Upper12.48 SEK
BB Middle11.54 SEK
BB Lower10.59 SEK
BB Width16.33%
ATR (14)0.5182 SEK
Vol Ratio (20d)0.34x